In metastatic pancreatic cancer, patients can be treated upfront with either FOLFIRINOX or gemcitabine combined with nab-paclitaxel (Abraxane). Results of the phase III MPACT study showed that gemcitabine/nab-paclitaxel improved progression-free and overall survival (OS) compared with gemcitabine alone (HR, 0.69; 95% CI, 0.58-0.82; P <.001) in patients with metastatic pancreatic cancer with a Karnofsky performance score ≥70.1 Median OS was 8.5 months and 6.7 months, respectively, in the combination and single-agent gemcitabine arms. Read more . . .